Intrinsic rewarding effects of estradiol (E 2 ) may underlie some of the sex differences that emerge postpuberty for the prevalence of drug use and behavioral responses to drugs, but the effects and mechanisms of E 2 for reward have not been well characterized. Conditioned place preference (CPP), as measured by the time spent on the nonpreferred/drug-associated side of the chamber, was utilized as a functional assay to investigate the effects and mechanisms of E 2 in the nucleus accumbens for reward. To determine whether intracellular estrogen receptors (ERs) are important for E 2 -induced CPP, rats were administered E 2 (10 mg; subcutaneously (s.c.)), which produced CPP in each experiment, and/or ER blockers, such as tamoxifen (Experiment 1), ICI 182,780 (Experiment 2), or antisense oligonucleotides targeted to ERs (Experiment 3). Experiment 1: E 2 significantly increased the time spent on the originally nonpreferred side of the chamber. Coadministration of tamoxifen (10 mg/kg; s.c.) attenuated effects of E 2 to produce a CPP, but tamoxifen alone, increased time spent on the nonpreferred side. Experiment 2: coadministration of ICI 182,780 (10 mg/ml) to the nucleus accumbens attenuated effects of E 2 to enhance CPP and did not produce a CPP when administered alone. Experiment 3: coadministration of s.c. E 2 with ER antisense oligonucleotides to the nucleus accumbens significantly decreased time spent on the nonpreferred side and expression of ERs in the nucleus accumbens compared to scrambled antisense oligonucleotides or saline vehicle administration. Thus, E 2 's rewarding effects may involve actions at ERs in the nucleus accumbens.
INTRODUCTION
There are sex differences in vulnerability to drug abuse among people and in animal models (SAMHSA, 2004 ; reviewed by Carroll et al, 2004) . Clinical and animal model studies suggest that adult females may also be more vulnerable to drugs of abuse than are their male counterparts. Women begin cocaine use at a younger age than do men (Griffin et al, 1989) and can become addicted to abused substances, such as cocaine, opiates, and alcohol, faster than do men (Lex, 1991) . Similarly, female rodents demonstrate quicker acquisition of cocaine, methamphetamine, and nicotine intravenous self-administration than do males (Caggiula et al, 2002; Carroll et al, 2001; Roth and Carroll, 2004) . Thus, these data suggest that females may be more vulnerable to effects of drugs of abuse. However, potential mechanisms for these effects are yet to be determined.
One possible reason for sex differences in drug abuse may involve estradiol's (E 2 ) effects to underlie or influence responses to drugs of abuse among people and animals. There are differences across the menstrual cycle in women's response to drugs. For instance, subjective responses to amphetamine (ie feelings of euphoria, liking/wanting, energy, and intellectual ability) are enhanced during the late follicular phase, when E 2 levels are rising, compared to the early follicular or luteal phase, when E 2 levels are lower de Wit, 1999, 2000a) . Indeed, there is a positive correlation between subjective responses to amphetamine and E 2 levels (Justice and de Wit, 1999) . Furthermore, transdermal administration of E 2 to women in the follicular phase enhances subjective responses to amphetamine (Justice and de Wit, 2000b) . Additionally, rodent models support a role for E 2 in drug abuse. Naturally receptive rodents that have moderate physiological levels of E 2 have increased hyperactivity after cocaine administration than do diestrous rats with lower levels of E 2 (Sell et al, 2002) . Removal of the primary source of E 2 , the ovaries (OVX), attenuates amphetamine-induced hyperactivity, cocaine-induced behavioral sensitization, and intravenous cocaine self-administration, which can be reversed by E 2 replacement (Becker, 1990; Lynch et al, 2001; Peris et al, 1991) . Thus, E 2 may influence responses to drugs of abuse.
Drug abuse and neuropsychiatric disorders are often comorbid and, notably, E 2 influences affect among women and in animal models . Women who abuse alcohol, cocaine, opiates, and/or nicotine have higher rates of mood and/or anxiety disorders than do men (Brooner et al, 1997; Borrelli et al, 1999; Cornelius et al, 1995; Lundy et al, 1995; McCance-Katz et al, 1999) . Among women who have anxiety/mood disorders, E 2 therapy can enhance mood, but is dependent on the regimen utilized (Ahokas et al, 2001; Gregoire et al, 1996; Saletu et al, 1995; Schleifer et al, 2002; Smith et al, 1995) . A similar pattern is observed in animal models. In naturally receptive rats, or OVX rats administered E 2 regimen that produce physiological E 2 levels, anxiety and depression behaviors are decreased (Estrada-Camarena et al, 2003; Frye et al, 2000; Walf, 2002, 2004; Frye and Wawrzycki, 2003; Nomikos and Spyraki, 1988; Rachman et al, 1998; Slater and Blizard, 1976; Frye, 2005a, b, 2006) . Thus, these data suggest that E 2 can alter affective responses.
E 2 may have rewarding effects in the conditioned place preference (CPP) paradigm, which is used to elucidate effects of substances on reward (White and Carr, 1985) . Subcutaneously (s.c.) administered E 2 regimen that result in physiological E 2 levels in the nucleus accumbens of OVX rats produces a CPP . The nucleus accumbens is critical for CPP and is a target of E 2 . For example, E 2 increases c-jun-immunoreactivity in the nucleus accumbens (Zhou and Dorsa, 1994) . Whether E 2 has requisite actions in the nucleus accumbens to mediate CPP is not known.
Given that E 2 can alter responses to drugs of abuse, as well as produce rewarding effects, it is important to determine the mechanisms for these effects. E 2 alters other reward-related processes that increase dopamine release in the nucleus accumbens or striatum of female rats, such as wheel-running, locomotion, and pacing of copulatory contacts (Becker et al, 1987 (Becker et al, , 2001 ; as reviewed by Becker, 1999; Jenkins and Becker, 2003; Mermelstein and Becker, 1995;  as reviewed by Lynch et al, 2002; Pfaus et al, 1995; Xiao and Becker, 1997) . Pharmacological blockade of estrogen receptors (ERs) in these regions with the selective antagonist, ICI 182,780, but not tamoxifen (which can have both agonistic and antagonistic effects at ERs) attenuates E 2 -facilitated pacing behavior (Xiao and Becker, 1997; Xiao et al, 2003) . Thus, one mechanism by which E 2 may influence reward processes is through actions at ERs.
A specific binding site for E 2 was identified over 40 years ago (Jensen and Jacobsen, 1962) and eventually became known as ERs. More recently, another E 2 binding site with which E 2 interacts to have its functional effects has been identified (as reviewed by Kuiper et al, 1998) . The original binding site is now referred to as ERa and the newly identified binding site is referred to as ERb. The nucleus accumbens expresses ERs (referring to both ERa and ERb; Shughrue et al, 1997 Shughrue et al, , 1998 . Thus, we utilized a number of pharmacological tools to block ER action in the nucleus accumbens to address E 2 's mechanisms in this region for reward.
In the present study, we investigated whether E 2 -induced CPP requires actions at ERs in the nucleus accumbens. Rats were s.c. administered E 2 and/or ER blockers, such as tamoxifen s.c. (Experiment 1), ICI 182,780 to the nucleus accumbens (Experiment 2), or antisense oligonucleotides targeted toward the originally identified binding site of E 2 infused to the nucleus accumbens (Experiment 3). We hypothesized that if actions at ERs in the nucleus accumbens are required for E 2 's rewarding effects, then coadministration of E 2 in conjunction with ER blockers would attenuate E 2 -induced CPP.
MATERIALS AND METHODS
These methods were preapproved by the Institutional Animal Care and Use Committee at SUNY-Albany.
Animals and Housing
Female Long-Evans rats (N ¼ 140), approximately 55 days old, were obtained from the breeding colony in the Social Sciences Building at SUNY-Albany (original stock from Taconic Farms, Germantown, NY). Rats were group-housed (4-5 per cage) in polycarbonate cages (45 Â 24 Â 21 cm) in a temperature-controlled room (21711C) in the laboratory animal care facility. Rats were maintained on a 12/12 h reversed light cycle (lights off 0800 hours) with continuous access to Purina rat chow and tap water.
Surgery
All rats were OVX under Rompun (12 mg/kg; Bayer Corp., Shawnee Mission, KS) and Ketaset (80 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA) anesthesia. For Experiments 2 and 3, rats were stereotaxically implanted with cannulae (23 G) aimed at the nucleus accumbens (from bregma AP ¼ + 1.7, ML ¼ 71.5, DV ¼ À6.0; as per Paxinos and Watson, 1986; . All rats were surgerized at least 1 week before testing.
ER Blockade
S.c. tamoxifen. In Experiment 1, rats were coadministered s.c. tamoxifen (10 mg/kg s.c.; Sigma Chemical Co., St Louis, MO), or vehicle (sesame oil and 10% ethanol), in conjunction with sesame oil vehicle or E 2 (10 mg/0.2 cm 3 ; Sigma). As such, there were four groups (n ¼ 18/group) in this experiment: s.c. vehicle + s.c. vehicle, s.c. tamoxifen + s.c. vehicle, s.c. vehicle + s.c. E 2 , and s.c. tamoxifen + s.c. E 2 . S.c. administration of tamoxifen was utilized because it is an effective, albeit nonselective, ER antagonist that is bloodbrain barrier soluble. This tamoxifen regimen has been utilized to block E 2 's effects on lordosis (Etgen and Shamamian, 1986) and anxiety behavior (Walf and Frye, 2005b) .
Intranucleus accumbens ICI 182,780. In Experiment 2, rats were coadministered ICI 182,780 (10 mg/ml; Tocris Bioscience, Ellisville, MO), or vehicle (b-cyclodextran) to the shell of the nucleus accumbens, in conjunction with s.c. injections of sesame oil vehicle or E 2 (10 mg/0.2 cm 3 ). As such, there were four groups in this experiment: intranucleus accumbens vehicle + s.c. vehicle (n ¼ 14), intranucleus accumbens ICI 182,780 + s.c. vehicle (n ¼ 12), intranucleus accumbens vehicle + s.c. E 2 (n ¼ 17), and intranucleus accumbens ICI 182,780 + s.c. E 2 (n ¼ 10). ICI 182,780 was utilized because it is a specific ER antagonist and has been used successfully in our laboratory to investigate E 2 's effects on mnemonic processes and affective behavior .
Intranucleus accumbens antisense oligonucleotides. In Experiment 3, rats were administered saline vehicle (n ¼ 4) or full phosphorothioate HPLC-purified mRNA antisense oligonucleotides (Genomechanix, Gainesville, FL). One group of rats was administered ER antisense oligonucleotides (n ¼ 6), with the sequence, 5
0 -CAT-GGT-CAT-GGT-CAG-3 0 , that spans the putative translation start codon for rat ERa, and knocks down the translation of ERa. Another group of rats was administered scrambled control antisense oligonucleotides (n ¼ 4), with a 15-mer sequence (5 0 -ATC-GTG-GAT-CGT-GAC-3 0 ) that has the same base pairs, but the order randomized, and little or no homology to any mRNA sequences posted at GeneBank (NCBI BLAST search). Rats were infused with ERa antisense oligonucleotides (2 mg/1 ml; McCarthy et al, 1993), scrambled control oligonucleotides (2 mg/1 ml), or saline vehicle immediately before administration of E 2 , 30 min before placement on the nonpreferred side of the CPP chamber on days 4-5 and 8-9 (as described below in detail).
CPP Paradigm
The CPP paradigm used in the present study was as described previously . This paradigm includes the following four phases: habituation, baseline preference test, place preference conditioning, and place preference test.
Habituation (days 1 and 2): Rats were allowed to explore both sides of the conditioning chamber for 30 min each day.
Baseline preference test (day 3): Rats were placed in the chamber for 30 min and the amount of time spent on each side of the chamber was electronically recorded.
Place preference conditioning (days 4-11): A typical place preference conditioning procedure was utilized. Rats were administered drugs with putative conditioning properties (ie E 2 and/or ER blockers in the present experiment) before placement in the nonpreferred side of the chamber (as determined on day 3) on days 4-5 and 8-9. On days 6-7 and 10-11, all rats, irrespective of their experimental condition on conditioning days, were administered vehicle (appropriate to the experiment) immediately prior to placement in the originally preferred side of the apparatus.
Place preference test (day 12): Rats were placed in the apparatus with free access to both sides. The amount of time spent on each side was electronically recorded for a total duration of 30 min. Time on the nonpreferred side is considered an index of CPP.
Site Analyses
After testing in Experiment 2, rats were perfused with 0.9% saline followed by 10% formalin. Brains were removed from the skull, fixed in formalin, and then sliced on a cryostat at 40 mm. Slices were then stained with cresyl violet and infusion location was determined with light microscopy. All but three rats received implants to the shell of the nucleus accumbens, which has previously been described as important for the modulation of CPP by steroids . The three rats that received bilateral implants to the core of the nucleus accumbens were not included in statistical analyses.
Tissue Collection, Dissection, and Digestion
In Experiment 3, rats were readministered their s.c. E 2 and intranucleus accumbens antisense oligonucleotide regimen. Rats were rapidly decapitated, and brains were quickly removed from the skull, and placed on dry ice. Whole brains were stored at À801C until the nucleus accumbens and pituitary (as a positive control) were dissected out. Cannulae placement was verified during dissection. For dissections, brains were first gently thawed on ice. The nucleus accumbens and pituitaries were each placed in eppendorf tubes containing protease inhibitor cocktail dissolved in distilled water (Roche, 11836145001). Samples were transferred to test tubes on ice and were homogenized. Homogenized samples were then stored in the original eppendorf tubes containing the protease inhibitor overnight at 41C.
Western Blot Analyses
To verify effective knockdown of ERs with the antisense oligonucleotide strategy utilized, differences in ER protein expression in the nucleus accumbens with Western blotting were assessed. Standard Western blotting techniques were employed using polyclonal anti-rabbit antibodies against ERa (C1355; Upstate Biotechnology, Lake Placid, NY; Tanabe et al, 2004; Tanaka et al, 2004) to establish the extent to which the antisense oligonucleotides bound to the translation start sites of ERa and inhibited its translation into protein (Schreihofer et al, 2002) . Western blotting analyses using a monoclonal anti-mouse b-actin antibody (A1978; Sigma) were also performed as a loading control. Briefly, homogenized samples were centrifuged for 20 min at 11 Â 1000g. Supernatant was separated from the pellet and stored at À201C. A Bradford assay was then performed to determine protein concentration in each sample (Bradford, 1976) . Using this information, 10 mg of protein and sample buffer (50 mM Tris-Cl (pH 6.8), 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, and 10% glycerol), yielding a final volume of 10 ml, were loaded onto 7.5 Â 10.0 cm gels. Samples were resolved on 10% SDS polyacrylamide gel utilizing 25 mM Tris-glycine buffer, pH 8.3, containing 20% methanol at 100 V for 1.5-2 h at room temperature, and electrophoretically transferred to nitrocellulose membrane (Pierce; with pore size of 0.45 mm) using a 25 mM Tris-glycine buffer, pH 8.3, containing 20% methanol, at 100 V for 1.5 h at 41C. After transfer was complete, nitrocellulose membranes were blocked in Pierce's blocking buffer (Pierce, Rockford, IL) with 0.05% Tween-20 overnight at 41C. The membranes were washed in buffer (phosphate-buffered saline with 0.05% Tween-20) on a rocking platform before incubation with the primary antibodies for ERa (1 : 1000 dilution) or b-actin (1 : 1000 dilution) in blocking buffer with 0.05% Tween-20 overnight at 41C. After incubation with the primary antibody, membranes were washed in buffer on a rocking platform and were incubated with the appropriate horseradish peroxidase-labeled goat anti-rabbit (1 : 3000 dilution for ERa) or goat anti-mouse secondary antibody (1 : 5000 dilution for b-actin) supplied in the chemiluminescence kit (Pierce, Supersignal West FEMTO Max Sensitivity kit; 34095), in blocking buffer with 0.05% Tween-20, for 1 h with agitation. Membranes were then washed in buffer, soaked in the chemiluminescence medium for 5 min, and exposed to X-ray film, and film was developed.
Statistical Analyses
To determine mechanisms and effects of E 2 for producing a place preference in these experiments, three-way analyses of variance (ANOVAs) were utilized in Experiments 1 and 2 to analyze effects of E 2 condition, ER blocker condition, and test occasion (baseline vs test). Two-way ANOVAs were used to determine effects of infusion (antisense or scrambled oligonucleotides or vehicle) to OVX, E 2 -primed rats and time on CPP. Previous studies in our lab utilizing CPP have suggested that an a level of Pp0.05 is appropriate . Where appropriate, ANOVAs were followed by Fisher's post hoc tests with Bonferroni corrections to determine group differences. Although sample sizes varied across experiments, post hoc power analyses indicated that there was sufficient power in each experiment, minimally 70%.
RESULTS

Experiment 1: Effects of Systemic Tamoxifen (Figure 1)
There were main effects of E 2 condition (F(1,136) ¼ 5.9, Po0.02) and test occasion (F(1,136) ¼ 35.6, Po0.01) that was owing to E 2 significantly increasing time on the nonpreferred side during testing compared to vehicle. Although there was no significant main effect of tamoxifen, there was an interaction between E 2 and tamoxifen [F(1,136) ¼ 12.8, Po0.01] that was owing to tamoxifen attenuating CPP in rats coadministered E 2 , but not vehicle. .01] on place preference of E 2 -primed, OVX rats. Rats administered E 2 and infused with ER antisense oligonucleotides to the nucleus accumbens spent significantly less time on the nonpreferred side of the chamber during testing than did E 2 -primed rats infused with scrambled antisense oligonucleotides or vehicle. Compared to the administration of vehicle or scrambled control to the nucleus accumbens, bands for ERa in nucleus accumbens were not apparent (see Figure 3 , inset), demonstrating that ERs were knocked down 24 h after s.c. E 2 administration and ERa antisense oligonucleotides infusion.
DISCUSSION
The present results supported our hypothesis that E 2 's effects to produce a CPP may be due in part to actions at ERs in the nucleus accumbens. S.c. administration of E 2 increased time spent on the originally nonpreferred side of the chamber and this was consistently attenuated with coadministration of ER blockers. First, s.c. tamoxifen decreased time spent on the nonpreferred side of the chamber in rats coadministered E 2 , but also produced intrinsic effects when coadministered with vehicle. Second, administration of the specific ER antagonist, ICI 182,780, to the nucleus accumbens significantly decreased the time spent on the nonpreferred side of the chamber of rats administered E 2 and did not produce intrinsic effects. Third, administration of ER antisense oligonucleotides to the nucleus accumbens of OVX, E 2 -primed rats significantly decreased time on the nonpreferred side and ERa expression in the nucleus accumbens compared to the administration of saline vehicle or scrambled control antisense oligonucleotides. Together, these data suggest that the ability of E 2 to produce a place preference may require actions at ERs in the nucleus accumbens.
The present data confirm previous studies on how E 2 may alter aspects of reward and have intrinsic rewarding effects.
Here, we demonstrate that s.c. E 2 administration to OVX rats increases time spent on the originally nonpreferred side of the CPP chamber, which replicates data from a previous experiment. We have previously shown that there are regimen-dependent effects of E 2 to OVX rats to produce CPP, which occur with dosages that produce physiological levels of E 2 in the nucleus accumbens, such as the 10 mg regimen utilized here . These findings complement those from other models that demonstrate E 2 also increases performance in other behavioral assays that are typically utilized to assess the rewarding properties of a substance, such as intracranial self-stimulation and self-administration. Naturally receptive and OVX, E 2 -administered rats have increased rates of intracranial self-stimulation than do rats with lower E 2 levels (Steiner et al, 1982 ; as reviewed by Carroll et al, 2004) . Hamsters intracerebroventricularly self-administer E 2 (Dimeo and Wood, 2006) . Furthermore, the present study extends these findings of the reinforcing effects of E 2 to suggest that actions at ERs in the nucleus accumbens may be important for E 2 -mediated effects on reward.
Systemic administration of the mixed ER agonistantagonist, tamoxifen, attenuated E 2 -induced place preference and enhanced place preference in rats administered vehicle, suggesting that tamoxifen had some intrinsic effects on reward. Tamoxifen, like other selective ER modulators (SERMS), can have both agonistic and antagonistic actions at ERs, depending upon tissue target. This may explain why systemically administered tamoxifen (which could have actions throughout the brain) did not completely block E 2 -induced CPP and produced modest increases in place preference when coadministered with vehicle in the present study. Similar patterns of results have been shown previously with systemic tamoxifen administration. Tamoxifen demonstrated E 2 mimetic effects in other systems. For example, systemic tamoxifen has effects similar to E 2 to increase NMDA receptors in the brain (Cyr et al, 2001) . In other situations, tamoxifen attenuates the effects of E 2 . Tamoxifen administered s.c. attenuates antianxiety behavior of OVX rats administered E 2 or SERMs specific to ERb (Walf and Frye, 2005b) . As well, coadministration of E 2 and tamoxifen via s.c. injections attenuated E 2 's effects on cocaine self-administration (Lynch et al, 2001 ). There are also scenarios when there is no effect of tamoxifen. For example, tamoxifen is ineffective in altering changes in dopamine release in the striatum or pacing behavior of OVX, E 2 -primed rats (Xiao et al, 2003) . Together, these data suggest that administration of ER ligands, such as E 2 and tamoxifen, can alter reward. However, whether ERs in the nucleus accumbens were required for effects of E 2 on reward were unclear, so this was further examined using more specific pharmacological tools.
Administration of the specific ER antagonist, ICI 182,780, to the nucleus accumbens attenuated E 2 -induced CPP, without producing intrinsic effects on CPP. Other studies have demonstrated that ICI 182,780 has functional effects to attenuate behaviors modulated by E 2 . ICI 182,780, but not tamoxifen, when administered to the dorsolateral striatum, blocks E 2 -facilitated pacing behavior (Xiao et al, 2003) . Additionally, administration of a specific ER antagonist, ICI 182,780, to the hippocampus increases anxiety and depression behavior of naturally receptive rats (Walf and Frye, Figure 3 The mean (7SEM) time spent on the nonpreferred side of the conditioning chamber. *Above bar indicates E 2 increases time spent on the nonpreferred side compared to intranucleus accumbens saline vehicle or scrambled control antisense oligonucleotide administration (Po0.05). Inset depicts Western blot analyses of ERa and actin protein expression in the nucleus accumbens of these groups.
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Mechanisms of estradiol-induced place preference AA Walf et al 2006). Although our results suggest that intracellular ERs are important, it is not entirely clear whether ICI 182,780 has antagonist effects at membrane and/or intracellular ERs . In addition to actions at intracellular ERs, E 2 can have rapid actions via membrane ERs or other membrane-bound receptors that initiate signal-transduction pathways (Beyer et al, 2002; Kelly and Levin, 2001; Moss and Gu, 1999; Nilsen et al, 2002; Toran-Allerand et al, 2002; Wade et al, 2001; Watters et al, 1997) . Furthermore, it has been postulated that some of E 2 effects at intracellular ERs are potentiated subsequent to the activation of membrane-associated ERs (Kow and Pfaff, 2004; Vasudevan et al, 2001 ). The nucleus accumbens expresses both ER isoforms; however, relatively low levels of intracellular ER mRNA or protein expression in the nucleus accumbens have been demonstrated (Shughrue et al, 1997 Shughrue and Merchenthaler, 2001 ). The expression of membrane ERs in this region is not clear and it may be that effects of E 2 in the nucleus accumbens are owing to an interaction of membrane and nuclear ERs. The design of the present experiment does not allow us to determine if E 2 's effects were rapid (ie occurring in less than 10-15 mins; Pfaff and McEwen, 1983) and through actions involving membrane receptors, but this could be addressed in future studies.
The third strategy that was utilized in the present experiments to investigate E 2 's ER-mediated effects for reward was knockdown of ERs with infusions of ER-specific antisense oligonucleotides. We found that administration of ERa antisense oligonucleotides to the nucleus accumbens produced significantly shorter time spent in the nonpreferred side of the chamber than did administration of vehicle or scrambled control antisense oligonucleotides. Another study has shown that a similar regimen of ERa antisense oligonucleotides via a single infusion to neonatal rats produced specific behavioral and morphological effects in adulthood (McCarthy et al, 1993) . In the present study, there was no evidence for nonspecific behavioral effects of the antisense oligonucleotides, based upon neurological testing, which may have obviated effects of E 2 for CPP. Another aspect of this experiment to consider is the timing of the effects. Based upon previous studies utilizing similar antisense oligonucleotides regimen, protein knockdown occurs between 12 and 48 h following antisense oligonucleotide administration (McCarthy et al, 1994 (McCarthy et al, , 2000 Ogawa et al, 1994) . Although we cannot know that, at the initial time of conditioning of E 2 and ER antisense oligonucleotides (30 min after administration), expression of ERs was knocked down, knockdown of ERs at 24 h is consistent with the actions of E 2 at ERs being blocked by ER antisense oligonucleotides on the second day in the nonpreferred side of the CPP chamber and Western blot analyses.
The present study, using three strategies to block ERs, suggests that actions of E 2 to produce a CPP may be dependent on activating intracellular ERs in the nucleus accumbens. However, these data need to be interpreted with some caution. There are limitations to the CPP paradigm as a model for addictive behaviors in humans (Bardo and Bevins, 2000; Ettenberg, 2004) , such as modest face validity and the question of whether this is a task that measures conditioning to context rather than drugs' interoceptive effects. Future studies could use other models of reward to investigate the mechanisms of E 2 for this effect further. Furthermore, there are potential differences in E 2 's effects in this paradigm owing to timing of treatment or regimen utilized. In this study, we have investigated short-term, acute treatment with E 2 . For instance, short-term effects of E 2 for affective behavior are not the same as that seen with with longer treatment and/or higher dosing regimen (Luine et al, 1998; Pfaff, 2001, 2002; . Indeed, E 2 produced place aversion and disrupted CPP, when high and/or chronic dosages were utilized (de Beun et al, 1991; Galea et al, 2001) . Thus, the effects of E 2 on behavior are mitigated by many factors, such as timing and dosage of E 2 utilized, which need further investigation to determine the effects of E 2 for chronic conditions, such as mood and anxiety disorders.
The importance of E 2 acting at ERa vs ERb needs to be addressed further. The pharmacological compounds used to block ERs vary in their specificity for blocking these isoforms. Although all blockers attenuated the effects of E 2 , it is not clear if ICI 182,780 is specific for ERa or ERb, there is suggestion that tamoxifen's antagonistic, but not agonistic, effects are through actions involving ERb (Watanabe et al, 1997) and the antisense oligonucleotides strategy was targeted toward ERa. However, these ER isoforms can interact for their functional effects (Lindberg et al, 2003 ; as reviewed by Toran-Allerand 2004) , suggesting that the possibility remains that either isoform may be important. Indeed, studies investigating the putative roles of ERa and ERb for cognitive processes, arousal, and affect suggest the importance of these ER isoforms. Studies utilizing SERMs or ER knockout mice support a role of both ERa and ERb for learning and memory processes (Fugger et al, 2000; Luine et al, 2003; Rhodes and Frye, 2006; and ERa for behavioral arousal (Ogawa et al, 2003; Pfaff et al, 2002) . Studies utilizing knockout mice or ERb SERMs suggest that E 2 's actions at ERb may be important for its antianxiety and antidepressant-like effects. ERb knockout mice have increased anxiety (Krezel et al, 2001) , and do not have reduced anxiety or depression behavior in response to E 2 administration, as do their wildtype counterparts (Imwalle et al, 2005; Rocha et al, 2005; . S.c. administration of ERb, but not ERa, SERMs decrease anxiety and depressive behavior of OVX rats (Lund et al, 2005; Walf and Frye, 2005b; Walf et al, 2004) . Some of E 2 's effects on reward processes and behavioral responses to drugs of abuse may be through interactions with the mesolimbic dopaminergic system (as reviewed by Becker, 1999) and ERb. A recent report suggests that an ERb-specific SERM produces similar effects as does E 2 to increase D 2 receptor density in the striatum and nucleus accumbens (Le Saux et al, 2006) . Thus, further investigation of E 2 's actions at ERa and/or ERb and integration with the mesolimbic dopamine system for reward are warranted.
An interesting question is what other modulators, besides putative actions through ERs and/or the mesolimbic dopamine system, may underlie the effects of E 2 for reward and/or affective behaviors. One possibility is that some of E 2 's effects on reward and affective processes may be mediated by actions of the hypothalamic pituitary adrenal axis (HPA). Although E 2 's effects on glucocorticoid release among female rodents may be regimen dependent (Walf and Frye, 2005a) , there is evidence that E 2 administration increases corticosterone levels of rats administered cocaine (Niyomchai et al, 2005) . Notably, studies investigating sex differences in relapse rates of drug users suggest that women are more likely to report relapse as a response to stressor exposure (Swan et al, 1988; Gritz et al, 1996; Snow and Anderson, 2000) . Future studies should investigate how the HPA may contribute to the effects of E 2 through actions involving ERs on reward and affective processes.
In summary, these data suggest that E 2 's actions to condition a place preference are due in part to actions at ERs in the nucleus accumbens. E 2 administered s.c. produces a place preference in OVX rats. Administration of compounds that block ERs, administered systemically or to the nucleus accumbens, attenuated E 2 -induced place preference. It is important to further investigate the sites and mechanisms of action for E 2 as a potential modulator of reward and affective processes.
